Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
Featured trial
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lymphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)

(MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these

cancer
waldenstrom's macroglobulinemia
lymphoma
lymphocytosis
marginal zone lymphoma
  • 115 views
  • 15 Apr, 2019
  • 1 location
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous

diffuse large b-cell lymphoma
lymphoma
multiple myeloma
leukemia
marginal zone lymphoma
  • 721 views
  • 13 May, 2022
  • 16 locations
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

kinase inhibitor
measurable disease
lymphoma
mantle cell lymphoma
leukemia
  • 32 views
  • 28 Jul, 2022
  • 34 locations
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

diffuse large b-cell lymphoma
anemia
renal function
b-cell small lymphocytic lymphoma
venetoclax
  • 188 views
  • 27 Jul, 2022
  • 57 locations
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

waldenstrom's macroglobulinemia
follicular lymphoma
marginal zone lymphoma
refractory lymphoma
leukemia
  • 0 views
  • 24 Mar, 2022
  • 15 locations
Dasatinib In Waldenström Macroglobulinemia

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK

bone marrow procedure
potassium
platelet count
ibrutinib
measurable disease
  • 2 views
  • 05 Apr, 2022
Bendamustine Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC

bendamustine
lymphoma
monoclonal protein
corticosteroids
rituximab
  • 0 views
  • 04 Aug, 2021
  • 5 locations
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

lymphoma
remission
indolent lymphoma
dexamethasone
fludarabine
  • 2 views
  • 24 Jan, 2021
  • 1 location
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (Ballondor)

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia

measurable disease
lenalidomide
dexamethasone
bortezomib
rituximab
  • 20 views
  • 23 Apr, 2022
  • 1 location
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 (OBI-1)

relapsed/refractory Waldenstrm Macroglobulinemia (R/R MW).

tumor cells
bone marrow procedure
anemia
obinutuzumab
monoclonal antibodies
  • 13 views
  • 14 Feb, 2022
  • 1 location